These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36636048)

  • 1. Identification of genes and cellular response factors related to immunotherapy response in mismatch repair-proficient colorectal cancer: a bioinformatics analysis.
    Xue W; Shi J
    J Gastrointest Oncol; 2022 Dec; 13(6):3038-3055. PubMed ID: 36636048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weighted Gene Co-expression Network Analysis Identifies CALD1 as a Biomarker Related to M2 Macrophages Infiltration in Stage III and IV Mismatch Repair-Proficient Colorectal Carcinoma.
    Zheng H; Bai Y; Wang J; Chen S; Zhang J; Zhu J; Liu Y; Wang X
    Front Mol Biosci; 2021; 8():649363. PubMed ID: 33996905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Tumor Cell-Intrinsic Expression of Cyclic GMP-AMP Synthase (cGAS)-Stimulator of Interferon Genes (STING) on the Infiltration of CD8
    Nakajima S; Kaneta A; Okayama H; Saito K; Kikuchi T; Endo E; Matsumoto T; Fukai S; Sakuma M; Sato T; Mimura K; Saito M; Saze Z; Sakamoto W; Onozawa H; Momma T; Kono K
    Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer.
    Takei S; Tanaka Y; Lin YT; Koyama S; Fukuoka S; Hara H; Nakamura Y; Kuboki Y; Kotani D; Kojima T; Bando H; Mishima S; Ueno T; Kojima S; Wakabayashi M; Sakamoto N; Kojima M; Kuwata T; Yoshino T; Nishikawa H; Mano H; Endo I; Shitara K; Kawazoe A
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38336371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits immune checkpoint blockade efficacy.
    Ho WW; Gomes-Santos IL; Aoki S; Datta M; Kawaguchi K; Talele NP; Roberge S; Ren J; Liu H; Chen IX; Andersson P; Chatterjee S; Kumar AS; Amoozgar Z; Zhang Q; Huang P; Ng MR; Chauhan VP; Xu L; Duda DG; Clark JW; Pittet MJ; Fukumura D; Jain RK
    Proc Natl Acad Sci U S A; 2021 Nov; 118(45):. PubMed ID: 34725151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depicting the landscape of gut microbial-metabolic interaction and microbial-host immune heterogeneity in deficient and proficient DNA mismatch repair colorectal cancers.
    Li J; Guo Y; Liu J; Guo F; Du L; Yang Y; Li X; Ma Y
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37597851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancers.
    Wala J; de Bruijn I; Coy S; Gagné A; Chan S; Chen YA; Hoffer J; Muhlich J; Schultz N; Santagata S; Sorger PK
    bioRxiv; 2024 Sep; ():. PubMed ID: 39386479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Immune Landscape Reveals Prognostic Significance of Cytotoxic CD4
    Qi J; Liu X; Yan P; He S; Lin Y; Huang Z; Zhang S; Xie S; Li Y; Lu X; Wu Y; Zhou Y; Yuan J; Cai T; Zheng X; Ding Y; Yang W
    Front Oncol; 2021; 11():724232. PubMed ID: 34631551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
    Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
    Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immuno-Contexture and Immune Checkpoint Molecule Expression in Mismatch Repair Proficient Colorectal Carcinoma.
    Giacomelli M; Monti M; Pezzola DC; Lonardi S; Bugatti M; Missale F; Cioncada R; Melocchi L; Giustini V; Villanacci V; Baronchelli C; Manenti S; Imberti L; Giurisato E; Vermi W
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
    Zhou G; Noordam L; Sprengers D; Doukas M; Boor PPC; van Beek AA; Erkens R; Mancham S; Grünhagen D; Menon AG; Lange JF; Burger PJWA; Brandt A; Galjart B; Verhoef C; Kwekkeboom J; Bruno MJ
    Oncoimmunology; 2018; 7(7):e1448332. PubMed ID: 29900067
    [No Abstract]   [Full Text] [Related]  

  • 14. Gut microbiota distinct between colorectal cancers with deficient and proficient mismatch repair: A study of 230 CRC patients.
    Jin M; Wu J; Shi L; Zhou B; Shang F; Chang X; Dong X; Deng S; Liu L; Cai K; Nie X; Zhang T; Fan J; Liu H
    Front Microbiol; 2022; 13():993285. PubMed ID: 36312959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful Treatment of pMMR MSS IVB Colorectal Cancer Using Anti-VEGF and Anti-PD-1 Therapy in Combination of Gut Microbiota Transplantation: A Case Report.
    Cheng X; Li X; Yang X; Fang S; Wang Z; Liu T; Zheng M; Zhai M; Yang Z; Shen T
    Cureus; 2023 Jul; 15(7):e42347. PubMed ID: 37621810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer.
    Möller K; Blessin NC; Höflmayer D; Büscheck F; Luebke AM; Kluth M; Hube-Magg C; Zalewski K; Hinsch A; Neipp M; Mofid H; Lárusson H; Daniels T; Isbert C; Coerper S; Ditterich D; Rupprecht H; Goetz A; Bernreuther C; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Minner S; Burandt E; Krech T; Perez D; Izbicki JR; Clauditz TS; Marx AH
    Acta Oncol; 2021 Sep; 60(9):1210-1217. PubMed ID: 34092167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy combined with local therapy in the late-line treatment of repair-proficient (pMMR)/microsatellite stable (MSS) metastatic colorectal cancer.
    Ding Y; Weng S; Zhu N; Mi M; Xu Z; Zhong L; Yuan Y
    Heliyon; 2023 Nov; 9(11):e22092. PubMed ID: 38058653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Inflammatory Markers of Resectable Colorectal Cancer Patients with Different Mismatch Repair Gene Status.
    Li J; Zhang Y; Xu Q; Wang G; Jiang L; Wei Q; Luo C; Chen L; Ying J
    Cancer Manag Res; 2021; 13():2925-2935. PubMed ID: 33833576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the molecular characteristics associated with microsatellite status of colorectal cancer patients for the clinical application of immunotherapy.
    Fu J; Jin X; Chen W; Chen Z; Wu P; Xiao W; Liu Y; Deng S
    Front Pharmacol; 2023; 14():1083449. PubMed ID: 36814498
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.